INVO Bioscience, Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by INVO Bioscience, Inc. (INVO) on July 26, 2023. The filing addresses a corporate action involving a reverse stock split and a recent decision by the Nasdaq Hearings Panel regarding the company's continued listing status.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, or debt metrics. The only financial threshold mentioned is the Nasdaq listing requirement of $2.5 million in stockholders' equity, which the company was previously non-compliant with.
Material Changes
- Reverse Stock Split: The company filed a Certificate of Change to effectuate a 1-for-20 reverse stock split of its common stock. This became effective at 12:01 a.m. Eastern Time on July 28, 2023.
- Capital Structure Adjustment: Following the split, the company's authorized common stock was adjusted to 6,250,000 shares. Outstanding stock options and warrants were proportionately adjusted.
- Trading Details: The stock continues to trade on the Nasdaq Capital Market under the symbol "INVO" but with a new CUSIP number (44984F401). Fractional shares are rounded up to the next whole share.
Outlook, Risks, and Management Commentary
- Nasdaq Compliance: On July 27, 2023, the Nasdaq Hearings Panel granted the company a request for continued listing. This decision was conditional on the company demonstrating compliance with the minimum $1.00 bid price and $2.5 million stockholders' equity requirements by September 29, 2023.
- Risk of Delisting: Management stated that while they are diligently working to meet these criteria, there can be no assurance that the company will be able to do so in time.
- Background: The listing exception followed a hearing on July 6, 2023, regarding the company's non-compliance with the aforementioned bid price and equity requirements.
Investor Verification Checklist
- Verify the effective date and trading start time of the 1-for-20 reverse stock split (July 28, 2023).
- Confirm the new CUSIP number (44984F401) for trading purposes.
- Monitor the company's progress toward meeting the $1.00 bid price and $2.5 million stockholders' equity requirements by the September 29, 2023 deadline.
- Review the impact of the reverse split on outstanding options and warrants held by investors.